Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE

PURPOSE: We evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogenic chemotherapy-induced nausea and vomiting. This phase III study was the first head-to-head comparison between two different neurokinin-1 receptor antagonists in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Akito, Okamoto, Isamu, Inui, Naoki, Okada, Morihito, Morise, Masahiro, Akiyoshi, Kohei, Takeda, Masayuki, Watanabe, Yasutaka, Sugawara, Shunichi, Shinagawa, Naofumi, Kubota, Kaoru, Saeki, Toshiaki, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718175/
https://www.ncbi.nlm.nih.gov/pubmed/34793245
http://dx.doi.org/10.1200/JCO.21.01315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718175/
https://www.ncbi.nlm.nih.gov/pubmed/34793245
http://dx.doi.org/10.1200/JCO.21.01315

Ejemplares similares